News
CNSY
2.030
0.00%
0.000
Press Release: Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
Dow Jones · 2d ago
Weekly Report: what happened at CNSY last week (0907-0911)?
Weekly Report · 4d ago
ServiceNow To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Friday
Benzinga · 09/11 12:21
Cerenome Price Target Cut to $43.00/Share From $57.00 by Ascendiant Capital
Dow Jones · 09/11 10:11
Cerenome Is Maintained at Buy by Ascendiant Capital
Dow Jones · 09/11 10:11
Ascendiant Capital Maintains Buy on Cerenome, Lowers Price Target to $43
Benzinga · 09/11 10:01
Cerenome Secures New Senior Financing to Extend Runway
TipRanks · 09/10 12:30
Cerenome Enters Into Financing Agreement With 3i LP For Senior Secured Facility Of Up To $20M With Royalty-Based Repayments
Benzinga · 09/10 11:18
Cerenome Enters Financing Agreement With 3i Fund For Senior Secured Facility Of Up To $20M With Royalty-Based Repayments
Benzinga · 09/10 11:17
Press Release: Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
Dow Jones · 09/10 11:15
Weekly Report: what happened at CNSY last week (0831-0904)?
Weekly Report · 09/07 09:01
Quant Check: Top- and bottom-rated small-cap healthcare stocks post-earnings
Seeking Alpha · 09/01 14:25
Weekly Report: what happened at CNSY last week (0824-0828)?
Weekly Report · 08/31 09:01
Weekly Report: what happened at CNSY last week (0817-0821)?
Weekly Report · 08/24 09:01
Cerenome Highlights REYOBIQ Clinical Data And CNSide Health Economics Findings At 2026 SNO/ASCO CNS Metastases Conference
Benzinga · 08/20 11:36
Weekly Report: what happened at CNSY last week (0810-0814)?
Weekly Report · 08/17 09:01
Plus Therapeutics GAAP EPS of -$1.31 misses by $0.45; reaffirms FY outlook
Seeking Alpha · 08/17 04:59
Cerenome (CNSY) Reports Q2 Loss, Misses Revenue Estimates
NASDAQ · 08/14 21:30
*Cerenome Affirming Milestone Framework, Outlook Provided When Reporting full-Yr 2026 Fincl Results >CNSY
Dow Jones · 08/14 20:16
Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
Barchart · 08/13 06:30
More
Webull provides a variety of real-time CNSY stock news. You can receive the latest news about Cerenome, Inc through multiple platforms. This information may help you make smarter investment decisions.
About CNSY
Cerenome, Inc., formerly Plus Therapeutics, Inc., is a healthcare company. The Company is focused on central nervous system (CNS) cancers through three business areas: precision diagnostics, targeted radiopharmaceutical therapeutics, and proprietary data analytics. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, including the CNSide cerebrospinal fluid (CSF) assay platform, designed to identify, characterize and monitor tumor cells in patients with CNS cancers. Its lead product candidate, rhenium (186Re) obisbemeda (REYOBIQ), is designed for CNS cancers, including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC), through direct localized delivery utilizing tissue access methods, including convection-enhanced delivery (CED) and others. Its Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat primary and metastatic solid organ cancers.